| Identification of bacteria-derived HLA-bound peptides in melanoma S Kalaora, A Nagler, D Nejman, M Alon, C Barbolin, E Barnea, ... Nature 592 (7852), 138-143, 2021 | 312 | 2021 |
| Urea cycle dysregulation generates clinically relevant genomic and biochemical signatures JS Lee, L Adler, H Karathia, N Carmel, S Rabinovich, N Auslander, ... Cell 174 (6), 1559-1570. e22, 2018 | 252 | 2018 |
| Mechanisms of immune activation and regulation: lessons from melanoma S Kalaora, A Nagler, JA Wargo, Y Samuels Nature Reviews Cancer 22 (4), 195-207, 2022 | 175 | 2022 |
| Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens S Kalaora, E Barnea, E Merhavi-Shoham, N Qutob, JK Teer, N Shimony, ... Oncotarget 7 (5), 5110, 2016 | 162 | 2016 |
| Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma S Kalaora, JS Lee, E Barnea, R Levy, P Greenberg, M Alon, G Yagel, ... Nature communications 11 (1), 896, 2020 | 142 | 2020 |
| Combined analysis of antigen presentation and T-cell recognition reveals restricted immune responses in melanoma S Kalaora, Y Wolf, T Feferman, E Barnea, E Greenstein, D Reshef, I Tirosh, ... Cancer discovery 8 (11), 1366-1375, 2018 | 100 | 2018 |
| Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics A Nagler, S Kalaora, C Barbolin, A Gangaev, SLC Ketelaars, M Alon, ... Cell Reports 35 (13), 2021 | 52 | 2021 |
| A genome‐wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS‐mutant melanoma A Nagler, DW Vredevoogd, M Alon, PF Cheng, S Trabish, S Kalaora, ... Pigment cell & melanoma research 33 (2), 334-344, 2020 | 32 | 2020 |
| Combined presentation and immunogenicity analysis reveals a recurrent RAS. Q61K neoantigen in melanoma A Peri, E Greenstein, M Alon, JA Pai, T Dingjan, S Reich-Zeliger, ... The Journal of clinical investigation 131 (20), 2021 | 25 | 2021 |
| CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma M Alon, R Arafeh, JS Lee, S Madan, S Kalaora, A Nagler, T Abgarian, ... Oncotarget 9 (58), 31264, 2018 | 12 | 2018 |
| Cancer exome-based identification of tumor neo-antigens using mass spectrometry S Kalaora, Y Samuels Cancer Immunosurveillance: Methods and Protocols, 203-214, 2019 | 9 | 2019 |
| Correction: CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma M Alon, R Arafeh, JS Lee, S Madan, S Kalaora, A Nagler, T Abgarian, ... Oncotarget 10 (13), 1344, 2019 | 1 | 2019 |
| Identification of recurrent mutated neopeptides Y Samuels, S Kalaora, P Aviyah, N Friedman, S Reich-zeliger, ... US Patent App. 17/612,279, 2022 | | 2022 |
| Characterization of immunotherapy targets in melanoma S Kalaora PQDT-Global, 2019 | | 2019 |
| 24 Combined analysis of antigen presentation and T cell recognition reveals restricted immune responses in melanoma S Kalaora, Y Wolf, A Reuben, SA Rosenberg, M Lotem, U Sahin, J Wargo, ... ESMO Open 3, A11, 2018 | | 2018 |
| Identification of unique HLA peptides presented on SCLC cells S Kalaora, A Admon TUMOR BIOLOGY 33, 93-94, 2012 | | 2012 |
| Mono-allelic expression of HLA-I alleles for HLA-peptidomics analysis A Nagler, S Kalaora, C Barbolin, M Alon, P Greenberg, G Yagel, A Peri, ... | | |